Rx Comparative Studies Will Be Funded By Neurontin Settlement
Executive Summary
The Pfizer Neurontin off-label promotion settlement will fund $28 mil. in comparative efficacy studies for prescription drug products
You may also be interested in...
Academic Archive of Pharma Marketing Data On Hold Without Funding
A UCSF group wants its Internet site to be a go-to place for internal documents that reveal the marketing behavior of pharma companies. But it may be awhile before the site can resume posting data unearthed in litigation.
Academic Archive of Pharma Marketing Data On Hold Without Funding
A UCSF group wants its Internet site to be a go-to place for internal documents that reveal the marketing behavior of pharma companies. But it may be awhile before the site can resume posting data unearthed in litigation.
Neurontin Off-Label Suit: Plaintiffs’ Experts Claim Pfizer Slanted Studies
Pharmaceutical companies appear to be facing wider legal pressure to alter the way they create and disseminate studies designed to support marketed products